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versus Autologous Transplantation for Diffuse Large
B Cell Lymphoma: A Report from the CIBMTR
Hillard M. Lazarus,1 Mei-Jie Zhang,2 Jeanette Carreras,2 Brandon M. Hayes-Lattin,3
Asli Selmin Ataergin,4 Jacob D. Bitran,5 Brian J. Bolwell,6 Cesar O. Freytes,7
Robert Peter Gale,8 Steven C. Goldstein,9 Gregory A. Hale,10 David J. Inwards,11
Thomas R. Klumpp,12 David I. Marks,13 Richard T. Maziarz,3 Philip L. McCarthy,14
Santiago Pavlovsky, MD,15 J. Douglas Rizzo,1 Thomas C. Shea,16 Harry C. Schouten,17
Shimon Slavin,18 Jane N. Winter,19 Koen van Besien,20 Julie M. Vose,21
Parameswaran N. Hari2We compared outcomes of 916 diffuse large B cell lymphoma (DLBCL) patients aged$18 years undergoing
first autologous (n 5 837) or myeloablative (MA) allogeneic hematopoietic cell transplant (HCT) (n 5 79)
between 1995 and 2003 reported to the Center for International Blood and Marrow Transplant Research
(CIBMTR). Median follow-up was 81 months for allogeneic HCT versus 60 months for autologous HCT. Al-
logeneic HCT recipients were more likely to have high-risk disease features including higher stage, more
prior chemotherapy regimens, and resistant disease. Allogeneic HCTwas associated with a higher 1 year
treatment-related mortality (TRM) (relative risk [RR] 4.88, 95% confidence interval [CI], 3.21-7.40, P\
.001), treatment failure (RR 2.06, 95% CI, 1.54-2.75, P\.001), and mortality (RR 2.75, 95% CI, 2.03-3.72,
P\.001). Risk of disease progression was similar in the 2 groups (RR 1.12, 95% CI, 0.73-1.72, P 5 .59). In
fact, for 1-year survivors, no significant differences were observed for TRM, progression, progression-free
(PFS) or overall survival (OS). Increased risks of TRM and mortality were associated with older age (.50
years), lower performance score, chemoresistance, and earlier year of transplant. In a cohort of mainly
high-risk DLBCL patients, upfront MA allogeneic HCT, although associated with increased early mortality,
was associated with a similar risk of disease progression compared to lower risk patients receiving autolo-
gous HCT.
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(DFS) in nearly 50% of patients with chemotherapy-
sensitive relapsed DLBCL [4-6]. The vast majority of
autologous HCT procedures use peripheral blood
(PB) rather than bone marrow (BM) as the graft source,
as this modality is superior in terms of faster hemato-
poietic recovery from myelosuppression, easier to per-
form, cheaper, and less hazardous [7-9]. Autologous
HCT, however, is less effective in patients with chemo-
resistant relapse [10-13]. This observation often is ex-
plained by an increase in relapse risk because of a lack
of graft-versus-lymphoma (GVL) effect, and because
of reinfusion of malignant cells [4,5,14-16]. Allogeneic
HCT, usually employing BM as the stem cell source, is
a potential therapeutic option especially for patients
with matched sibling donors and higher risk disease.
Potential advantages of allogeneic HCT include the
use of a tumor-free graft and a GVL effect that may re-
duce the risk of relapse in addition to a reduction of the
risk of secondary leukemia by hematopoietic stem cell
(HSC) replacement [16-21]. Acute or chronic graft-
versus-host disease (aGVHD, cGVHD) and high rates
of opportunistic infection, however, may lead to high
transplant- or treatment-related mortality (TRM)
and morbidity, and offset the benefits of this approach
[16-21]. Although there are many reports describing
outcomes after autologous HCT for DLBCL patients,
there are fewer publications that describe the results us-
ing myeloablative (MA) allogeneic HCT [22-29].
To date, there are few prospective, randomized re-
ports comparing autologous versus allogeneic HCT
for DLBCL. The Ontario BMT Network reported
the results of a large trial [17]. Most other reports
that compare autologous versus allogeneic HCT are
small, retrospective, and single institution trials com-
prising heterogeneous histologic NHL subtypes
[17,18,30-33]. The main objectives of this study were
to compare the clinical outcomes between patients
with DLBCL receiving autologous versus allogeneic
matched sibling donor HCT and to determine pa-
tient-, disease- and transplant-related variables associ-
ated with favorable outcomes.PATIENTS AND METHODS
Data Sources
The Center for International Blood and Marrow
Transplant Research (CIBMTR) is a voluntary work-
ing group of over 500 transplant centers worldwide.
Participating centers register basic information on
consecutive transplants to a Statistical Center at the
Medical College of Wisconsin. Detailed demographic
and clinical data are collected on a representative sam-
ple of patients in the registry using a weighted random-
ization scheme. Participating centers are required to
report all consecutive transplant data; compliance ismonitored by on-site audits. Patients are followed lon-
gitudinally, with yearly follow-up.
The CIBMTR collects data at 2 levels: registration
and research. Registration data includes disease type,
age, sex, pretransplant disease stage and chemother-
apy-responsiveness, date of diagnosis, graft type
(BM, PB, and cord blood [CB]-derived hematopoietic
stem cells), conditioning regimen, posttransplant dis-
ease progression and survival, development of second-
ary cancers, and cause of death. Requests for data on
progression or death for registered subjects are at 6-
month intervals. All CIBMTR teams contribute regis-
tration data. Research data are collected on subsets of
registered subjects and includes comprehensive pre-
and posttransplant clinical data. Computerized checks
for errors, physician reviews of submitted data and on-
site audits of participating centers ensure the quality of
data.Patients
The outcomes of 916 adult DLBCL patients be-
tween the ages of 18 and 60 years, receiving autologous
or matched sibling allogeneic HCT reported to the
CIBMTR between January 1, 1995, and December
31, 2003, were analyzed. Patients receiving reduced-
intensity conditioning (RIC) or T cell-depleted grafts
were excluded. Patients receiving allogeneic HCT af-
ter a prior autologous transplant also were excluded.
Patients were reported to the CIBMTR by 156 centers
in 17 different countries.
Transplant types were categorized as autologous (n5
837) or HLA-identical sibling allogeneic transplants (n5
79). Median follow-up was 60 (range: 1-130) months for
autologous HCT versus 81 (range: 14-120) months for
allogeneic HCT.Study Endpoints
Outcomes included TRM, progression, progression-
free survival (PFS), and overall survival (OS). TRM was
defined as death within 28 days posttransplant or death
without lymphoma progression. Progression was defined
as progressive lymphoma posttransplant (.28 days) or
lymphoma recurrence and could follow a period of ‘‘sta-
ble’’ disease posttransplant, or a partial or complete re-
mission (PR, CR). For PFS, subjects were considered
treatment failures at the time of lymphoma progression
or death from any cause. OS was defined as time from
the date of transplant to the date of death or last contact.
Other outcomes analyzed included aGVHD and
cGVHD and cause of death (COD). aGVHD was de-
fined and graded using established criteria. cGVHD
was defined as the development of any cGVHD based
on clinical criteria.
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Patient-, disease- and treatment-related variables
for the 2 study groups were compared using the chi-
square statistic for categoric and the Kruskal-Wallis
test for continuous variables. Univariate probabilities
of PFS and OS were calculated using the Kaplan-Me-
ier estimator. Probabilities of aGVHD and cGVHD,
TRM, and relapse/progression were calculated using
cumulative incidence curves to accommodate compet-
ing risks.Cox Proportional Hazards Model
Assessment of potential risk factors for outcomes
of interest was evaluated in multivariate analyses us-
ing Cox proportional hazards regression. Variables
considered in multivariable analysis are listed in Ta-
ble 1. A backward stepwise model selection approach
was used to identify all significant risk factors. Each
step of model building contained the main effect
for donor type. Factors significant at a 5% level
were kept in the final model. The potential interac-
tions between main effect and all significant risk fac-
tors were tested. The proportionality assumption was
tested by adding a time-dependent covariate for each
factor. When test indicated differential effects over
time (nonproportional hazards), models were con-
structed breaking the posttransplant course into 2
time periods, using the maximized partial likelihood
method to find the most appropriate breakpoint. The
proportionality assumptions were further tested. After
the above modeling of time-varying effects, the final
multivariate model was built. Adjusted probabilitiesTable 1. Variables Tested in Cox Proportional Hazards Re-
gression Models
Main effect variable*
Transplant type: Autologous versus HLA-identical sibling allogeneic
Patient-related variables
Age at transplant: 18-30 years, 31-50 years, >50 years
Karnofsky performance status at transplant: $90% versus <90%
Sex: male versus female
Disease-related
Disease stage at diagnosis: I or II versus III or IV
Chemosensitive disease at transplant: Sensitive vs resistant
B symptoms at diagnosis: present versus absent
Time from diagnosis to transplant: continuous
Extranodal disease or splenic involvement at diagnosis: yes versus no
Marrow involvement at diagnosis: yes versus no
Treatment-related
Source of stem cells: bone marrow versus peripheral blood
Year of transplant: 1995-2000 versus 2001-2003
HLA-identical sibling only
Donor-recipient sex match: F-M versus others
GVHD prophylaxis: MTX + CSA ± other versus MTX ± other versus
CsA ± other versus FK506 ± other versus none
Donor/recipient CMV status: 2/2 versus others
Autologous only
Purging: yes versus no
GVHD indicates graft-versus-host disease; MTX, methotrexate; CsA,
cyclosporine; CMV, cytomegalovirus.
*Included in all models.of PFS and OS were generated from the final Cox
models stratified on treatment of donor type and
weighted by the pooled sample proportion value for
each prognostic factor. These adjusted probabilities es-
timate likelihood of outcomes in populations with sim-
ilar prognostic factors.
Matched Pair Analysis
Clinical characteristics of the patient and disease
lead to selection of patients for an allogeneic transplant
as opposed to autologous HCT. In a retrospective
dataset, this selection bias results in significant pretrans-
plant differences between the autologous and allogeneic
cohorts. To validate the findings based on multivariate
analysis of the Cox model, we performed an additional
matched pair comparison of the allogeneic HCT group
with a subset of closely matched autologous HCT
patients selected based on propensity score matching.
The propensity score is the probability of receiving
an allogeneic transplant, which was calculated based
on fitting a logistic-regression model [34]. We fit a
logistic-regression with key risk factors of age, sex,
Karnofsky performance score (KPS) pretransplant,
disease stage at diagnosis, B symptoms at diagnosis, ex-
tranodal disease at diagnosis, marrow involvement at
diagnosis, number of prior chemotherapy regimens,
sensitivity to chemotherapy prior to transplant, time
from diagnosis to transplant, graft source, and year
of transplant (Table A of the supplemental data).
The median propensity score for the combined sample
was 0.042 (range: 0.002-0.895; SD5 0.1228). For each
allogeneic transplant (case) patient, any autologous
transplant (control) patient with a difference in the
propensity score of less than SD5 0.1228 was consid-
ered a potential matched control. The matched con-
trol with the smallest difference in propensity score
among all potential matched controls was selected.
These steps were repeated among the remaining cases
until 4 possible matched controls were identified for
each of the cases. Allogeneic recipients (69 cases)
were then matched in random order to autotransplant
(232 controls) recipients with similar propensity
scores. The final matched cohorts included 69 alloge-
neic transplant recipients and 232 autotransplant
recipients (49 cases were found with 4 matches, 2 cases
were found with 3 matches, 12 cases were found 2
matches and 6 cases were found 1 to 1 matches). Mul-
tivariate analysis was again performed by fitting a Cox
model stratified on matched-pairs.RESULTS
Patient, disease, and transplant characteristics of
the autologous and allogeneic cohorts are summa-
rized in Table 2. As expected, there were significant
differences between the cohorts receiving autologous
Table 2. Patient, Disease, and Transplant Characteristics
Autologous Allogeneic
Variable N Eval N (%) N Eval N (%) P-Value†
Patient related
Number of patients 837 79
Age, median (range), years 837 48 (18-60) 79 46 (21-59) .05
Male sex 837 483 (58) 79 49 (62) .46
Karnofsky score pretransplant 817 77 .18
<90 298 (36) 34 (44)
Disease related
Disease stage at diagnosis 822 79 .003
I 90 (11) 8 (10)
II 185 (23) 8 (10)
III 219 (27) 14 (18)
IV 326 (39) 49 (62)
Age-adjusted IPI¶ 391 38 .02
Low 50 (13) 0
Low-intermediate 137 (35) 12 (32)
High-intermediate 180 (46) 20 (55)
High 24 (6) 6 (16)
Missing 446 41
B Symptoms at diagnosis 775 355 (46) 76 44 (58) .04
Extranodal disease or splenic involvement at
diagnosis
800 452 (57) 77 54 (70) .02
Marrow involvement at diagnosis 800 139 (17) 77 32 (42) <.001
TBI at conditioning 833 151 (18) 79 46 (58) <.001
Conditioning regimen for autologous 837 NA —
TBI-based 151 (18)
BEAM and similar 515 (61)
CBV or similar 82 (10)
Others‡ 89 (11)
Conditioning regimen for allogeneic NA 79 —
TBI + Cy 41 (52)
Bu + Cy 24 (30)
Others§ 14 (18)
Autologous Allogeneic
Variable N Eval N (%) N Eval N (%) P-Value*
Number of prior chemotherapy regimens 836 79 .12
1 133 (16) 7 (9)
2 360 (43) 32 (40)
3 232 (28) 22 (28)
4 83 (10) 15 (19)
5 23 (3) 3 (4)
Best response to first line of chemotherapy 836 79 .007
CR 344 (41) 24 (30)
CRU/nodal PR 55 (7) 4 (5)
PR 265 (32) 28 (36)
No response/stable disease 45 (5) 13 (17)
Progression 70 (8) 8 (10)
Not Evaluable / Unknown 57 (7) 2 (2)
Interval from diagnosis to transplant, median
(range), months
837 13 (2-287) 79 11 (2-156) .03
Chemosensitive disease at transplant 837 79 <.001
Sensitive 709 (85) 46 (58)
Resistant 128 (15) 33 (42)
Disease status at transplant 830 76 <.001
PIF-sensitive 180 (21) 19 (25)
PIF-resistant 66 (8) 20 (26)
CR1 149 (18) 5 (7)
CR2+ 138 (17) 6 (8)
REL-sensitive 238 (29) 14 (18)
REL-resistant 59 (7) 12 (16)
Transplant related
Donor/Recipient CMV status NA 78 —
2/2 24 (31)
Donor-recipient gender match NA 79 —
F-M 26 (33)
Source of stem cells 837 79 <.001
(Continued )
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Table 2. (Continued )
Autologous Allogeneic
Variable N Eval N (%) N Eval N (%) P-Value*
BM 76 (9) 29 (37)
Year of transplant 837 79 .04
1995-1997 386 (46) 35 (44)
1998-2000 300 (36) 21 (27)
2001-2003 151 (18) 23 (29)
GVHD prophylaxis NA 79 —
MTX + CsA ± other 46 (58)
CsA ± other 18 (23)
FK506 ± other 13 (17)
None 2 (2)
Median follow-up of survivors, months 423 60 (1-130) 19 81 (14-120)
N indicates number; EVAL, evaluable; IPI, International Prognostic Index; TBI, total body irradiation; BEAM, BCNU + etoposite + Ara-C + melphalan;
CBV, cyclosphamide + BCNU+ VP16, etoposide; Cy, cyclosphosphamide; Bu, busulfan; CR, complete remission; CRU, complete remission undeter-
mined; PR, partial remission; PIF, primary induction failure; REL, relapse; F, female; M, male; BM, bone marrow; MTX, methotrexate; CsA, cyclosporine;
FK506, tacrolimus.
Follow-up completeness index 5 80% (overall); 80% (auto); 90% (allo). Overall 5 96% at 1 year; 86% at 3 years; 73% at 5 years.
*Selection/Exclusion criteria:
1. First autologous or HLA-identical sibling allogeneic transplant for diffuse large B cell lymphoma transplanted between 1995 and 2003 included.
2. 53 patients with reduced-intensity conditioning (RIC) regimens excluded
3. 16 patients with T cell depletion excluded
4. 367 patients with age <18 years or >60 years were excluded
5. 9 patients with untreated and 2 with not evaluable chemosensitive disease were excluded
† The chi-square test was used for discrete covariates; the Kruskal-Wallis test was used for continuous covariates.
‡ Other conditioning regimen for autologous (N589):
1. Ara-C + carboplatin (n51)
2. Bu alone (n53)
3. Carboplatin6other (n56)
4. Cy + Bu (n538)
5. Cy + carboplatin (n54)
6. L-PAM only (n520)
7. Bu-Mel (n57)
8. L-PAM 6 other (n58)
9. VP16 + Bu (n51)
10. VP16 + Carboplatin (n51)
§ Other conditioning regimen for HLA-identical siblings (N514):
1. Bu 6 other (no Cy) (n52)
2. Carboplatin + thiotepa (n51)
3. Cy 6 other (no Bu) (n55)
4. L-PAM 6 other (n51)
5. TBI 6 other (no Cy) (n55)
¶ A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med.
1993; 329:987-994.
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gous HCT had lower disease stage, lower age-ad-
justed International Prognostic Index (aaIPI), and
a lower likelihood of B symptoms, extra nodal dis-
ease, or marrow involvement. At transplantation, au-
tologous HCT patients were more likely to have
chemosensitive disease or be in CR. They also were
less likely to have received prior radiation and were
transplanted later in their disease course. Matched
sibling allograft recipients were more likely to be in
primary induction failure or with relapsed lymphoma
not having achieved a CR. The supplemental
matched pair analysis consisted of a cohort of 69 allo-
geneic sibling transplant recipients and 232 autolo-
gous HCT recipients with no differences in age,
sex, KPS, lymphoma stage, chemotherapy sensitivity,
time from diagnosis to transplant, or year of trans-
plant (Table B of the supplemental data).Table 3 summarizes univariate probabilities of all
outcomes of interest after transplantation.Treatment-Related Mortality
At 1, 3, and 5 years after transplant, TRM was
higher after HLA-identical sibling HCT (41%, 43%,
and 45%, respectively) than after autologous HCT
(12%, 16%, and 18%, respectively) (Figure 1). TRM
was significantly higher in the first 12 months after
HLA identical transplants compared to autologous
HCT (relative risk [RR] 4.88, 95% confidence interval
[CI] 3.21-7.40, P\ .001). In the subsequent period be-
yond 12 months, the risk of TRM was not different.
Other significant covariates associated with a higher
TRM included greater age at transplant, lower KPS
(\90), chemotherapy-resistant disease, and
Table 3. Outcomes after Autologous and HLA-Identical
Sibling Allogeneic HCTs for Diffuse Large B Cell Lymphoma
Autologous Allogeneic
Outcome Event Prob (95% CI) Prob (95% CI)
Acute GVHD at 100 days, grades (2-4) NA 42 (31-52)
Chronic GVHD NA
at 1 year 23 (15-33)
at 3 years 26 (17-36)
at 5 years 26 (17-36)
TRM
at 1 year 12 (9-14) 41 (30-51)
at 3 years 16 (14-19) 43 (32-54)
at 5 years 18 (15-20) 45 (34-56)
Progression/Relapse
at 1 year 33 (29-36) 30 (21-41)
at 3 years 37 (34-41) 33 (23-43)
at 5 years 40 (36-43) 33 (23-43)
PFS
at 1 year 56 (53-59) 29 (20-39)
at 3 years 47 (43-50) 24 (15-34)
at 5 years 43 (39-46) 22 (13-32)
Overall survival
at 1 year 66 (63-70) 33 (23-43)
at 3 years 53 (49-56) 26 (17-36)
at 5 years 49 (46-53) 22 (14-33)
TRM indicates transplant- or treatment-related mortality; PFS, progres-
sion-free survival; PROB, probability; GVHD, graft-versus-host disease;
CI, confidence interval.
Probabilities of acute GVHD, chronic GVHD, transplant- or treatment-
related mortality, and progression/relapse were calculated using the cu-
mulative incidence estimate. Progression-free survival and overall sur-
vival was calculated using the Kaplan-Meier product limit estimate.
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Figure 2. Cumulative incidence of progression/relapse after autolo-
gous and HLA-identical sibling HCTs for diffuse large B cell lymphoma.
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the supplemental data).Relapse/Progression
Figure 2 summarizes the cumulative incidence of re-
lapse at 1, 3, and 5 years after transplant. There were no
significant differences in the risk of relapse/progression
after allogeneic transplants compared to autologous
HCT. Significant covariates associated with a higher
risk of relapse/progression included greater age at trans-
plant (.50 years) and chemotherapy resistant disease
(see Table D of the supplemental data).Cu
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Figure 1. Cumulative incidence of transplant- or treatment-related
mortality after autologous and HLA-identical sibling HCTs for diffuse
large B cell lymphoma.PFS and Treatment Failure
At 1, 3, and 5 years after transplant, PFS was lower
after allogeneic HCT (29%, 24%. and 22%, respec-
tively) than after autologous HCT (56%, 47%, and
43%, respectively) (Figure 3). PFS was significantly
worse in the first 12 months after HLA identical trans-
plants compared to autologous HCT. In the subse-
quent period beyond 12 months, the risk was no
different between the 2 groups. Other significant cova-
riates associated with a lower PFS included greater age
at transplant (.50 years), chemotherapy-resistant
disease and transplants performed prior to 2001 (see
Table E of the supplemental data).Survival
At 1, 3, and 5 years after transplant, survival was
lower after HLA-identical sibling HCT (33%, 26%,
and 22%, respectively) than after autologous HCT
(66%, 53%, and 49%, respectively) (Figure 4). Survival
was significantly lower in the first 12 months after
HLA-identical transplants compared to autologous
HCT. In the subsequent period beyond 12 months,
the risk of mortality was not different. Other signifi-
cant covariates associated with a higher mortality and
lower survival included greater age (.50 years) at
transplant, lower KPS (\90), chemotherapy-resistant
disease, and transplants performed prior to 2001 (see
Table F of the supplemental data).Years
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Figure 3. Probability of PFS after autologous and HLA-identical sibling
HCTs for diffuse large B cell lymphoma.
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Figure 4. Probability of OS after autologous and HLA-identical sibling
HCTs for diffuse large B cell lymphoma.
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The incidence of grade II-IV aGVHD was 42%,
whereas the incidence of cGVHD was 26% at 5 years
after allogeneic transplant.Matched-Pair Analysis
The matched-pair analysis comparing HLA-iden-
tical sibling-matched allogeneic HCT versus matched
autologous HCT recipients confirmed the results of
the multivariate Cox model (Table 4). Lymphoma re-
lapse/progression rates did not differ between the 2
groups. However, within the first 12 months after
transplant, allogeneic HCT was associated with higher
TRM, lower PFS, and higher risk of treatment failure.
The risk of mortality was also higher in the allogeneic
cohort within the first 12 months of transplant. There
were no differences beyond 12 months.Cause of Death
The main cause of death among allogeneic versus
autologous HCT was primary disease in both groups
(48% versus 73%, respectively). Other causes of deathTable 4. Summary of Outcomes from Matched Pair Comparison
Outcome
TRM
(1) Allogeneic versus autologous (overall)
(2) Within first 12 months after transplant
Beyond first 12 months after transplant
Progression/relapse:
(1) Allogeneic versus autologous (overall)
(2) Within first 12 months after transplant
Beyond first 12 months after transplant
Treatment failure and PFS
(1) Allogeneic versus autologous (overall)
(2) Within first 12 months after transplant
Beyond first 12 months after transplant
Mortality (survival):
(1) Allogeneic versus autologous (overall)
(2) Within first 12 months after transplant
Beyond first 12 months after transplant
TRM indicates transplant- or treatment-realted mortality; PFS, progression-fr
TRM: overall test (2 d.f.): P<.0001; test early effect 5 late effect: P 5 .0542.
Progression/relapse: overall test (2 d.f.): P 5 .7737; test early effect 5 late effe
PFS: overall test (2 d.f.): P 5 .0015; test early effect 5 late effect: P 5 .4384.
Survival: overall test (2 d.f.): P < .0001; test early effect 5 late effect: P 5 .08were interstitial pneumonia (7% versus 6%), infection
(15% versus 3%), organ failure (8% versus 6%),
GVHD (10% versus 0%), and secondary malignancy
(0% versus 2%).DISCUSSION
We compared the outcomes of 916 DLBCL pa-
tients receiving an initial autologous (n 5 837) or
MA HLA-identical sibling allogeneic (n 5 79) HCT
from 1995 to 2003. Factors considered when recom-
mending an autologous versus allogeneic
transplantation for DLBCL include potential differ-
ences in TRM, concerns over tumor contamination
in an autograft, inability to mobilize hematopoietic
progenitor cells, and the expected benefits of a GVL
effect from an allograft. Allogeneic transplantation
therefore is likely to be offered to patients perceived
to be at lower risk for TRM and higher risk for disease
relapse/progression. Although nonmyeloablative
(NMA) and RIC regimens are increasingly used in al-
logeneic HCT for NHL, approximately two-thirds of
allografts for DLBCL reported to the CIBMTR uti-
lized MA regimens demonstrating the wide prevalence
of this approach [35].
The patient-, disease-, and transplant-related dif-
ferences observed between the cohorts reflect a clear
effect of patient selection, with the allotransplant
cohort having lower median age, higher incidence of
extra nodal, and marrow involvement and more resis-
tant, higher risk disease. The differences between the
groups in terms of graft source and the greater use of
total body irradiation (TBI) in conditioning are intrin-
sic to the MA transplant approach.Relative Risk (95% CI) P-Value
3.91 (2.16-7.08) <.0001
5.11 (2.63-9.94)
1.05 (0.24-4.56)
<.0001
.9499
1.18 (0.70-1.98) .5347
1.16 (0.68-1.97)
2.00 (0.11-37.83)
.5842
.6440
1.95 (1.34-2.83) .0005
2.04 (1.38-3.01)
1.19 (0.32-4.40)
.0003
.7948
2.38 (1.68-3.53) <.0001
2.77 (1.81-4.25)
1.05 (0.38-2.93)
<.0001
.9232
ee survival.
ct: P 5 .7204.
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balances between the cohorts in 2 separate statistical
analyses that yielded very similar results. In multivariate
Cox model comparing all the autograft recipients to the
allograft cohort, overall TRM after allogeneic trans-
plant was significantly higher than after autologous
HCT. This was especially driven by a higher TRM in
the first 12 months after allogeneic transplant with no
difference in survivors beyond 12 months. In their pro-
spective study, the Johns Hopkins group [18] reported
100-day TRM in 183 relapsed DLBCL patients as
33.3% for the allogeneic HCT recipients versus
17.4% for the autologous HCT recipients (P5 .03). Af-
ter 100 days, TRM remained significantly higher for the
allograft HCT recipients (17.8% versus 6.5%, P \
.001) [13]. Ratanatharathorn and associates [32] re-
ported in their prospective comparison that 12 of 16
deaths in the allogeneic HCT group were not related
to NHL compared to only 4 of 22 in the autologous
HCT population. These results are similar to our
data with 31 of the 60 deaths in the allogeneic group
were unrelated to lymphoma compared to 110 of 414
deaths in the autologous group. Other studies that com-
pared autologous versus allogeneic HCT for NHL that
included low- as well as aggressive-grade NHL also
found TRM after MA allogeneic HCT was a significant
factor for early death [17,19,20,36].
Many authors have noted that relapse rates after
allogeneic transplant for NHL are lower than after
autologous transplant [17,20,32,37-39]. Our study
shows that the relapse/progression rate after allogeneic
transplant was similar to that after autologous despite
higher risk disease (higher stage, aaIPI, and chemo-
therapy resistant disease) in the allograft group. The
prospective comparative trial reported by Ratanathara-
thorn and associates [32] reported similar rates of PFS,
but a higher rate of disease progression after autolo-
gous transplant in NHL, suggesting a GVL effect.
The prospective 100 patient trial reported by Gold-
stein et al. [33], which also included Hodgkin disease
(HD) patients, showed an improved freedom from pro-
gression in the recipients of allografts compared to the
subjects treated using autologous HCT, but there were
no statistical differences in PFS or OS between the 2
populations. Other evidence for GVL has included re-
ports of remissions after donor leukocyte infusion
(DLI) or RIC allotransplant for NHL, particularly in
low-grade NHL [40-43]. On the other hand, an analy-
sis of syngeneic versus allogeneic HCT showed no sig-
nificant difference in NHL relapse rates [19]. This
study suggested that tumor contamination, rather
than a GVL effect, may contribute to differences in re-
lapse between allogeneic and autologous procedures.
The 5-year PFS and OS were superior in those
DLBCL patients undergoing autologous HCT com-
pared to MA allogeneic sibling-matched HCT (43%
versus 22% and 49% versus 22%, respectively). Mostrelapse events occurred in the early postransplant pe-
riod, and any potential benefit in relapse after alloge-
neic HCT was offset by a higher early TRM in the
first 12 months. Our results differ from the matched
comparison reported by Schimmer et al. [17] in which
TRM and OS were similar. Unlike our series, which
was restricted to DLBCL, their heterogeneous popu-
lation included about one-third indolent NHL as
well as other histologic subtypes. The European Blood
and Marrow Transplant Registry (EBMTR) matched
analysis included 1185 allogeneic HCT patients but
only 147 intermediate-grade NHL recipients [38]. Al-
though the 4-year actuarial survival of 38% for alloge-
neic HCT was better than we noted, the matched pair
analysis data still demonstrated superiority of the au-
tologous HCT procedure.
A clinically driven patient selection bias for alloge-
neic HCT explains some of our observations. For ex-
ample, Schimmer and coworkers [17] reported that
those patients with BM involvement, or in whom the
stem cell harvest was inadequate, were offered an allo-
geneic HCT if they had a related donor and had che-
mosensitive tumor. Further, they comment that in
some cases, patient, physician, or a combination mod-
ified the HCT prescription. Advancing age often is
a reason not to offer an MA allogeneic HCT to
a NHL patient. In recent years, the use of RIC has in-
creased in the older patient subset, although
this approach is suggested to be significantly more ef-
ficacious for indolent NHL rather than DLBCL
[42,44,45]. These clinical preferences and patient or
disease features may have led to the selection of alloge-
neic transplants in a lower age, higher risk lymphoma
subset. These patterns of patient selection are reflec-
tive of practices across a large number of centers and
provide an opportunity to analyze the efficacy of the
allogeneic approach. Therefore, it is notable that de-
spite the significantly higher proportion of high risk
patients in the allogeneic group attributable to patient
selection, the overall risk of relapse or progression of
DLBCL was similar to the autologous group. The ef-
ficacy of the allogeneic approach in preventing lym-
phoma progression could be attributable to greater
use of TBI, lack of tumor contamination in the allo-
graft, and a GVL effect operating in the allogeneic
group.
Relapse remains the biggest drawback for successful
autologous HCT, and in this series the 5-year relapse
rate was 39%. Attempts to induce autologous GVHD
and corresponding GVL have not been successful [46].
Other investigators have incorporated post-HCT treat-
ment as well as implementation of targeted therapies
such as radioimmunoconjugates into the preparative
regimens to lower relapse rates after autologous HCT
[47,48]. The results of such trials, including a 131I-
Tositumomab and BEAM-containing Blood and Mar-
row Transplant Clinical Trials Network (BMT CTN)
Biol Blood Marrow Transplant 16:35-45, 2010 43Autologous versus Sibling Allogeneic HCT for DLBCLstudy, are ongoing. The increasing use of Rituximab has
likely changed the profile of patients currently receiving
autologous and allogeneic HCT for B cell lymphoma,
especially follicular lymphoma (FL). However, the im-
pact of this agent on the utilization of and outcomes after
HCT for DLBCL is not clear at this time.
In summary, for DLBCL patients, autologous
HCT was associated with superior survival compared
to MA HLA-identical, sibling-matched allogeneic
HCT. For a cohort of high risk DLBCL patients re-
ceiving MA matched sibling allogeneic transplants, re-
lapse risk was similar to the autologous group despite
the differences in disease characteristics between the
groups. The high incidence of early TRM after alloge-
neic transplants reduces the overall efficacy of this mo-
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